Skip To Content
Back to all companies

Get in touch with from Blusense


    Provider of next-generation POCT platform designed to diagnose infectious diseases. The company's platform is developing a consumer-oriented point-of-care blood testing device based on a nanotechnology biosensing method that can deliver results in a few minutes with a single drop of blood, enabling people to monitor, control and manage virus outbreaks better.

    The firm's innovative dengue/COVID-19 rapid diagnostic tool is specifically designed for use in emerging markets and provides a climate adaptive product that helps equip affected populations with the required instruments to adjust to more frequent incidences of vector borne diseases.

    3, Fruebjergvej, KĂžbenhavn, Denmark
    Countries of operation
    Malaysia, Vietnam, Thailand, India, Costa Rica, Panama, Colombia, Peru
    Year Founded

    ASAP Classifications

    Human and Managed Systems
    Impacts to human health, and loss of livelihoods, Spread of pests, and vector-borne and water- borne diseases

    Additional Info

    Generating revenue?
    Prefer not to say
    Company stage
    This company information was gathered from public sources and has not been verified by Blusense

    Last updated: May 25, 2021

    We don't support Internet Explorer

    Please use Chrome, Safari, Firefox, or Edge to view this site.